SCM
TEVA icon

Stonebridge Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Stonebridge Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-40,235
Closed -$1.34M – 141
2017
Q2 		$1.34M Buy
40,235
+14,070
+54% +$436K 0.51% 50
2017
Q1 		$840K Buy
26,165
+8,955
+52% +$306K 0.34% 60
2016
Q4 		$624K Buy
+17,210
New +$687K 0.26% 66
2016
Q1 		– Sell
-3,600
Closed -$236K – 167
2015
Q4 		$236K Hold
3,600
– – 0.1% 142
2015
Q3 		$203K Hold
3,600
– – 0.09% 147
2015
Q2 		$213K Hold
3,600
– – 0.09% 151
2015
Q1 		$224K Hold
3,600
– – 0.09% 149
2014
Q4 		$207K Buy
+3,600
New +$201K 0.08% 168
2014
Q2 		– Sell
-6,471
Closed -$342K – 191
2014
Q1 		$342K Sell
6,471
-5,629
-47% -$260K 0.14% 138
2013
Q4 		$485K Buy
12,100
+500
+4% +$19.7K 0.19% 106
2013
Q3 		$438K Buy
11,600
+300
+3% +$11.7K 0.2% 108
2013
Q2 		$443K Buy
+11,300
New +$440K 0.21% 106

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Stonebridge Capital Management's TEVA Position: Q3 2017 in Review

Stonebridge Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 40,235 shares — an estimated $1.34M sold.

Stonebridge Capital Management first reported a position in TEVA in Q2 2013 and held it in 12 quarters. The position peaked at $1.34M in Q2 2017. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Stonebridge Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Stonebridge Capital Management sold 40,235 Teva Pharmaceuticals shares in Q3 2017, an estimated $1.34M.
  • Stonebridge Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Stonebridge Capital Management's Teva Pharmaceuticals position peaked at $1.34M in Q2 2017.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Stonebridge Capital Management's 13F filing for Q3 2017, filed 1 Nov 2017.